The role of atypical antipsychotics in the treatment of bipolar disorder

Author/s
Jonathan Rogers, Rashid Zaman
Citation
Issue 3 Summer 2013
CEPiP.2013;1:159-167
Abstract

In the 1990s, a new group of antipsychotics emerged, also known as second-generation and described as atypicals because of the low incidence of extrapyramidal side-effects (EPSE). These drugs were considered to be a great step forward in the treatment of schizophrenia; the low incidence of EPSE allowed patients to avoid the stigma of the well-recognised movement problems caused by the typical antipsychotics. Almost a decade later, these atypical drugs began to be used widely in bipolar disorder. In this paper we review their pharmacology, neurobiology and uses in various forms of bipolar disorder.

Keywords: bipolar disorder, atypical antipsychotics

Cite as: Cutting Edge Psychiatry in Practice 2013, 3(1):159-167; https://doi.org/10.65031/bext4306

References

  1. Rang HP, Dale MM. Pharmacology. Churchill Livingstone, Elsevier; 2007. p. 829.                
  2. Meltzer H. Mechanism of action of atypical antipsychotic drugs. … . The Fifth Generation of Progress (KL Davis, D …. 2002) 
  3. Rebec G V, Bashore TR, Zimmerman KS, Alloway KD. “Classical” and “atypical” antipsychotic drugs: differential antagonism of amphetamine- and apomorphine-induced alterations of spontaneous neuronal activity in the neostriatum and nucleus accumbens. Pharmacology, biochemistry, and behavior. 1979 Nov;11 (5):529–38. https://doi.org/10.1016/0091-3057(79)90036-4
  4. Tyrer P, Kendall T. The spurious advance of antipsychotic drug therapy. Lancet. 2009 Jan 3;373 (9657):4–5. https://doi.org/10.1016/s0140-6736(08)61765-1
  5. Owens DC. Antipsychotics: is it time to end the generation game? Prescriber2. 2011;22 (19):48–50. 
  6. Nandra KS, Agius M. The differences between typical and atypical antipsychotics: the effects on neurogenesis. Psychiatria Danubina. 2012 Sep;24 Suppl 1:S95–9.          
  7. Brugue E, Vieta E. Atypical antipsychotics in bipolar depression: neurobiological basis and clinical implications. Progress in neuro-psychopharmacology & biological psychiatry. 2007 Jan 30;31 (1):275–82. https://doi.org/10.1016/j.pnpbp.2006.06.014
  8. NICE. Bipolar disorder. London: NICE; 2006 [cited 2013 Feb 2]. Available from: http://www.nice.org.uk/cg038    
  9. Yatham LN, Goldstein J, Vieta E, Bowden C, Grunze H, Post R, et al. Atypical Antipsychotics in Bipolar Depression: Potential Mechanisms of Action. J Clin Psychiatry. 2005.               
  10. Shim SS, Hammonds MD, Tatsuoka C, Feng IJ. Effects of 4-weeks of treatment with lithium and olanzapine on long-term potentiation in hippocampal area CA1. Neuroscience letters. 2012 Aug 22;524 (1):5–9. https://doi.org/10.1016/j.neulet.2012.06.047
  11. Li X, Rosborough KM, Friedman AB, Zhu W, Roth KA. Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics. The International Journal of Neuropsychopharmacology. 2007 Feb 1;10 (01):7–19. https://doi.org/10.1017/s1461145706006547
  12. Bridle C, Palmer S, Bagnall A, Darba J, Duffy S, Sculpher M, et al. Newer drugs for treatment of mania associated with bipolar affective disorder. 2004;8 (19). https://doi.org/10.3310/hta8190
  13. Jones RM, Thompson C, Bitter I. A systematic review of the efficacy and safety of second generation antipsychotics in the treatment of mania. European psychiatry : the journal of the Association of European Psychiatrists. 2006 Jan;21 (1):1–9. https://doi.org/10.1016/j.eurpsy.2005.02.002
  14. Berk M, Dodd S. Efficacy of atypical antipsychotics in bipolar disorder. Drugs. 2005 Jan;65 (2):257–69. https://doi.org/10.2165/00003495-200565020-00006
  15. Gentile S. Atypical antipsychotics for the treatment of bipolar disorder: more shadows than lights. CNS Drugs. 2007 Jan;21 (5):367–87. https://doi.org/10.2165/00023210-200721050-00002
  16. Dhillon S. Aripiprazole: a review of its use in the management of mania in adults with bipolar I disorder. Drugs. 2012 Jan 1;72 (1):133–62. https://doi.org/10.2165/11208320-000000000-00000
  17. Lin D, Mok H, Yatham LN. Polytherapy in bipolar disorder. CNS drugs. 2006 Jan;20 (1):29–42. https://doi.org/10.2165/00023210-200620010-00003
  18. Möller H-J, Grunze H, Broich K. Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review. European archives of psychiatry and clinical neuroscience. 2006 Feb;256 (1):1–16. https://doi.org/10.1007/s00406-005-0591-9
  19. Tohen M, McDonnell DP, Case M, Kanba S, Ha K, Fang YR, et al. Randomised, double-blind, placebo- controlled study of olanzapine in patients with bipolar I depression. The British journal of psychiatry : the journal of mental science. 2012 Nov;201 (5):376–82. https://doi.org/10.1192/bjp.bp.112.108357
  20. Sanford M, Keating GM. Quetiapine: a review of its use in the management of bipolar depression. CNS Drugs. 2012 May 1;26 (5):435–60. https://doi.org/10.2165/11203840-000000000-00000
  21. Fountoulakis KN, Kontis D, Gonda X, Siamouli M, Yatham LN. Treatment of mixed bipolar states. The International Journal of Neuropsychopharmacology. 2012 Aug 1;15 (07):1015–26. https://doi.org/10.1017/s1461145711001817
  22. McIntyre RS, Yoon J. Efficacy of antimanic treatments in mixed states. Bipolar Disorders. 2012 May;14 Suppl 2:22–36. https://doi.org/10.1111/j.1399-5618.2012.00990.x
  23. Beynon S, Soares-Weiser K, Woolacott N, Duffy S, Geddes JR. Pharmacological interventions for the prevention of relapse in bipolar disorder: a systematic review of controlled trials. Journal of psychopharmacology (Oxford, England). 2009 Jul;23 (5):574–91. https://doi.org/10.1177/0269881108093885
  24. Plosker GL. Quetiapine: a pharmacoeconomic review of its use in bipolar disorder. PharmacoEconomics. 2012 Jul 1;30 (7):611–31. https://doi.org/10.2165/11208500-000000000-00000
  25. Dias V V, Balanzá-Martinez V, Soeiro-de-Souza MG, Moreno RA, Figueira ML, Machado-Vieira R, et al. Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview. Acta psychiatrica Scandinavica. 2012 Nov;126 (5):315–31. https://doi.org/10.1111/j.1600-0447.2012.01910.x
  26. Bhalerao S, Seyfried LS, Kim HM, Chiang C, Kavanagh J, Kales HC. Mortality risk with the use of atypical antipsychotics in later-life bipolar disorder. Journal of geriatric psychiatry and neurology. 2012 Mar;25 (1):29–36. https://doi.org/10.1177/0891988712436687
  27. Joint Formulary Committee. British National Formulary (online). BMJ Group and Pharmaceutical Press. London: BMJ Group and Pharmaceutical Press.
  28. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. J Affect Disord. 2010, Nov; 126 (3) :358-65 https://doi.org/10.1016/j.jad.2010.04.005